{"id":"NCT00622700","sponsor":"Sanofi","briefTitle":"Phase III Study With Teriflunomide Versus Placebo in Patients With First Clinical Symptom of Multiple Sclerosis","officialTitle":"An International, Multi-center, Randomized, Double-blind, Placebo-controlled, Parallel Group Study to Evaluate the Efficacy and Safety of Two Year Treatment With Teriflunomide 7 mg Once Daily and 14 mg Once Daily Versus Placebo in Patients With a First Clinical Episode Suggestive of Multiple Sclerosis Plus a Long Term Extension Period","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2008-02","primaryCompletion":"2012-12","completion":"2016-02","firstPosted":"2008-02-25","resultsPosted":"2014-12-19","lastUpdate":"2017-03-13"},"enrollment":618,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"DOUBLE","primaryPurpose":"TREATMENT"},"conditions":["Multiple Sclerosis"],"interventions":[{"type":"DRUG","name":"Teriflunomide","otherNames":["HMR1726","Aubagio"]},{"type":"DRUG","name":"Placebo","otherNames":[]}],"arms":[{"label":"Placebo/Teriflunomide 7 mg or Teriflunomide 14 mg","type":"PLACEBO_COMPARATOR"},{"label":"Teriflunomide 7 mg/7 mg","type":"EXPERIMENTAL"},{"label":"Teriflunomide 14 mg/14 mg","type":"EXPERIMENTAL"}],"summary":"The primary objective was to demonstrate the effect of teriflunomide (HMR1726) (14 milligram per day \\[mg/day\\] and 7 mg/day), in comparison to placebo, for reducing conversion of participants presenting with their first clinical episode consistent with multiple sclerosis (MS) to clinically definite multiple sclerosis (CDMS).\n\nThe secondary objectives were:\n\n* To demonstrate the effect of teriflunomide, in comparison to placebo, on:\n\n  * Reducing conversion to definite multiple sclerosis (DMS)\n  * Reducing annualized relapse rate (ARR)\n  * Reducing disease activity/progression as measured by Magnetic Resonance Imaging (MRI)\n  * Reducing accumulation of disability for at least 12 weeks as measured by the Expanded Disability Status Scale (EDSS)\n  * Proportion of disability-free participants as assessed by the EDSS\n  * Reducing participant-reported fatigue\n* To evaluate the safety and tolerability of teriflunomide\n* To evaluate the pharmacokinetics (PK) of teriflunomide\n* Optional pharmacogenomic testing aimed at assessing the association between the main enzyme systems of teriflunomide metabolism and hepatic safety, and other potential associations between gene variations and clinical outcomes","primaryOutcome":{"measure":"Core Treatment Period: Time to Conversion to Clinically Deﬁnite Multiple Sclerosis (CDMS)","timeFrame":"Up to a maximum of 108 weeks depending on time of enrollment","effectByArm":[{"arm":"Placebo","deltaMin":14.3,"sd":null},{"arm":"Teriflunomide 7 mg","deltaMin":8.7,"sd":null},{"arm":"Teriflunomide 14 mg","deltaMin":9,"sd":null}],"pValues":[{"comp":"OG000 vs OG002","p":"0.0087"},{"comp":"OG000 vs OG001","p":"0.0271"}]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":3,"exclusionCount":6},"locations":{"siteCount":131,"countries":["United States","Australia","Austria","Bulgaria","Canada","Chile","Czechia","Denmark","Estonia","Finland","France","Germany","Hungary","Lithuania","Mexico","Poland","Romania","Russia","Turkey (Türkiye)","Ukraine","United Kingdom"]},"refs":{"pmids":["25192851"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":18,"n":191},"commonTop":["Nasopharyngitis","Headache","Alanine aminotransferase increased","Diarrhoea","Upper respiratory tract infection"]}}